Key result
Cardioinhibitory HUTT response linked to ~8.5-fold higher vasovagal syncope recurrence risk vs. vasodepressor response.
Why the study?
Vasovagal syncope impairs quality of life, and the response during head-up tilt testing influences quality of life and recurrence.
Does the type of response to head-up tilt test (cardioinhibitory vs vasodepressor) influence quality of life and recurrence of events in patients with vasovagal syncope?
Cohort (n=82)
No
Does the type of response to head-up tilt test (cardioinhibitory vs vasodepressor) influence quality of life and recurrence of events in patients with vasovagal syncope?
Hazard Ratio: 8.48 (95% CI 7.59–9.38)
Absolute Event Rate: 56.5% vs 27.8%
p-value: p=0.011
In patients with vasovagal syncope, a cardioinhibitory response during tilt testing is associated with better quality of life but a higher risk of syncope recurrence compared to a vasodepressor response.
May signal higher recurrence risk warranting closer monitoring; leaves open whether tilt responses should guide therapy or affect quality of life.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Miranda et al. (2024) conducted a cohort in Vasovagal syncope (n=82). Cardioinhibitory response during head-up tilt test vs. Vasodepressor response was evaluated on Vasovagal syncope recurrence (HR 8.48, 95% CI 7.59-9.38, p=0.011). Patients with a cardioinhibitory response during head-up tilt test had a significantly higher risk of vasovagal syncope recurrence (HR 8.48) compared to those with a vasodepressor response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: